stockrowRecursion Pharmaceuticals, Inc.
RXRX Healthcare Biotechnology
Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.
- Revenue
- +258.5%
- EPS
- +39.1%
- Free cash flow
- +33.8%
- Total debt
- −99.2%
Quarter to September 2026, against a year earlier
Follow RXRX
Alert me
Recursion Pharmaceuticals, Inc. (RXRX) Shares outstanding
Recursion Pharmaceuticals, Inc.'s shares outstanding at the end of fiscal 2025 was $447.4M, up 63.2% from $274.2M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $543.0M. Over the past ten years it has ranged from $21.6M (fiscal 2019) to $447.4M (fiscal 2025) — the current reading is the highest in ten years. Recursion Pharmaceuticals, Inc. ranks 9th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $447.4M | 63.18% |
| FY2024 | $274.2M | 31.92% |
| FY2023 | $207.9M | 18.41% |
| FY2022 | $175.5M | 40.04% |
| FY2021 | $125.3M | 475.48% |
| FY2020 | $21.8M | 0.98% |
| FY2019 | $21.6M | (86.99%) |
| FY2019 | $165.8M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $543.0M | 1.98% |
| Jun 2026 | $532.5M | 0.60% |
| Mar 2026 | $529.3M | 18.29% |
| Dec 2025 | $447.4M | 0.10% |
| 23 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| RXRX Recursion Pharmaceuticals, Inc. | $543.0M |
| ADMA ADMA Biologics Inc compare | $225.8M |
| BHVN Biohaven Ltd. compare | $151.0M |
| NAMS NewAmsterdam Pharma Company N.V. compare | $124.1M |
| CLDX Celldex Therapeutics, Inc. compare | $77.8M |
| PHVS Pharvaris N.V. compare | $68.1M |
| VCEL Vericel Corporation compare | $53.0M |
| MBX MBX Biosciences, Inc. compare | $47.7M |
| PVLA Palvella Therapeutics, Inc. compare | $14.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on RXRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement